GLP-1 Receptor Agonists for Intracranial Hypertension?

Clinical Takeaway

: A meta-analysis strongly supports the use of GLP-1 and dual GIP/GLP-1 RAs for treatment of IIH.

Context

Idiopathic intracranial hypertension (IIH) is on the rise, along with increasing rates of obesity — a major risk factor for IIH. Emerging preclinical and clinical data suggest a therapeutic role for glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs.

To evaluate the safety and efficacy of these agents for treatment of IIH, investigators conducted a systematic review and meta-analysis. They identified four studies comprising 1550 patients total, including one randomized, placebo-controlled trial (RCT; N=15). Primary outcome measures were presence of papilledema, visual disturbances or blindness, and headache. Duration of follow-up varied from 3 months to 2 years…

Reviewing Author

Teshamae Monteith, M.D.

Disclosures

Consultant/Advisory BoardAbbVie; Axsome; Teva; Linpharma; e-Neura; Novartis; Merz; Lundbeck; Axsome; Pfizer. Unpaid co-author for collaborative research sponsored by AbbVie, Pfizer/Biohaven, and Theranica.

RoyaltiesSpringer

Editorial BoardsCephalalgia; Continuum Audio; Neurology Minute; Neurology; American Migraine Foundation; Brain and Life Magazine

Leadership Positions in Professional SocietiesFlorida Society of Neurology (member, Executive Board); American Migraine Foundation (member, Executive Board); United Councils of Neurologic Subspecialities Examination Committee (Vice Chair)

OtherPaid speaking/education for Medscape, Massachusetts Medical Society, American Headache Society, and American Academy of Neurology